with BE and that this complex dissociates on specimen dilution with water or saline solution. This may be similar to the reported masking effects of benzalkonium chloride (Visine TM ) with the enzyme-multiplied immunoassay technique and TDx TM (Abbott Laboratories) assays for 9-carboxy-tetrahydrocannabinol; the drug is proposed to partition into micelles formed by benzalkonium chloride so that it is not accessible to antibodies (3 ) . The matrix components of different slide lots may vary in our experiments and affect dissociation of the complex between BE and binding components in urine. Intermolecular association may provide a mechanism for interference with selected components in lateral flow assay, accounting for interference with BE but not benzodiazepine and opiate detection. Because the two urine specimens from the above individual tested positive for cocaine, opiates, and benzodiazepine, that person was excluded from the drug study. To the Editor: Mutations in the glucokinase gene lead to an impaired sensing of blood glucose by the pancreatic ␤ cell, causing an autosomal dominant form of type 2 diabetes, maturity-onset diabetes of the young type 2 (MODY2). Usually, MODY2 patients present with high fasting blood glucose (6 -12 mmol/L) from an early age (1 ). This situation should significantly increase their risk for diabetic complications (2 ), but whereas other forms of diabetes typically lead to macrovascular complications, MODY2 patients rarely develop diabetes-related problems (3 ) .
In a family with autosomal dominant diabetes, we identified a novel C3 A substitution in the glucokinase gene at nucleotide position 695 [A232D (pancreatic isoform), A231D (liver isoform)] in all affected individuals (Fig. 1) . Codon 232 is highly conserved among nine different species. The mutation was not detected in 192 control chromosomes. Studied mutations around codon 232 (T228M and G261R) cause the lowest glucokinase activities of all mutations tested to date and suggest similar effects of A232D (4 ) .
On the basis of our findings, we determined that individuals 0307 and 0309 were probably misdiagnosed with type 1 diabetes and individuals 0301 and 0304 with gestational diabetes. However, individual 0305 was an unaffected mutation carrier, which is not uncommon for MODY.
High Fig.  1B) , we made the same observation (6 ). In both families, the difference for triglycerides was significant (P ϭ 0.025, two-sided test; 7 unaffected and 13 affected individuals), but we had no homozygous mutation carrier and too few cases to make a general statement.
It is possible that glucokinase mutations lead to lower triglycerides, even within their reference interval (0.35-2.30 mmol/L). Glucokinase mutations impair glycolysis, which is responsible for delivering glyceraldehyde 3-phosphate as the later glycerol backbone of triglycerides (4 ) . Transgenic mice overexpressing glucokinase develop hypertriglyceridemia in addition to other effects, indicating a direct link between glucokinase activity and triglyceride regulation (7 ) . There is evidence that serum concentrations of triglycerides are directly correlated with rates of progression of coronary artery disease and other macrovascular complications (8 -10 ) . In the studied family, and in concordance with the much lower frequency of diabetic complications in known MODY2 families, only one individual (0205) had a macrovascular event (myocardial infarction).
In conclusion, impaired glucokinase activity could lead to particularly low triglycerides in the circula- Black-shaded symbols represent MODY2 patients. Individuals 0206 (A) and I.2 (B) had classic type 2 diabetes but were not MODY2 cases (dark-gray-shaded symbols). Individual 0305 (A) was a mutation carrier for A232D but had no clinical signs of type 2 diabetes (light-gray-shaded symbol). MN in circles/rectangles indicates a heterozygous mutation; NN indicates the wild-type genotype. Genotyped microsatellite markers on chromosome 7 are given on the left. The disease haplotype is shown in black. The sequence with the mutation (exon 7, forward strand) is shown for individual 0305 and the wild-type sequence for individual 0306. The location of the glucokinase gene is indicated by an arrow in the haplotype of individual 0401. CA/AM, current age/age at manifestation; BMI, body mass index; T2D, type 2 diabetes; OHA, oral hypoglycemic agents; CHD, coronary heart disease; GD, gestational diabetes; NE, diabetic neuropathy; FF, fenofibrate therapy.
to the development of diabetic complications warrants further investigation.
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